Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Low-molecular-weight heparin in the management of Trousseau's syndrome.

Walsh-McMonagle D, Green D.

Cancer. 1997 Aug 15;80(4):649-55.

PMID:
9264346
2.

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.

Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D.

Arch Intern Med. 2002 Aug 12-26;162(15):1729-35.

PMID:
12153376
3.
4.

Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome.

Züger M, Demarmels Biasiutti F, Wuillemin WA, Furlan M, Lämmle B.

Ann Hematol. 1997 Oct;75(4):165-7.

PMID:
9402851
6.

Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.

van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, Piovella F, Prins MH, Büller HR.

Thromb Haemost. 2009 Apr;101(4):762-9.

PMID:
19350123
7.

Safety and efficacy of enoxaparin treatment in venous thromboembolic disease during acute leukemia.

Imberti D, Vallisa D, Anselmi E, Moroni CF, Bertè R, Lazzaro A, Bernuzzi P, Arcari AL, Cavanna L.

Tumori. 2004 Jul-Aug;90(4):390-3.

PMID:
15510981
8.
10.

Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.

Etchells E, McLeod RS, Geerts W, Barton P, Detsky AS.

Arch Intern Med. 1999 Jun 14;159(11):1221-8.

PMID:
10371230
11.

Trousseau's syndrome: cancer-associated thrombosis.

Ikushima S, Ono R, Fukuda K, Sakayori M, Awano N, Kondo K.

Jpn J Clin Oncol. 2016 Mar;46(3):204-8. doi: 10.1093/jjco/hyv165. Epub 2015 Nov 6. Review.

PMID:
26546690
13.
14.

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.

Davidson BL, Büller HR, Decousus H, Gallus A, Gent M, Piovella F, Prins MH, Raskob GE, Segers AE, Lensing AW; Matisse Investigators.

J Thromb Haemost. 2007 Jun;5(6):1191-4.

15.

Continuous subcutaneous heparin infusion for treatment of Trousseau's syndrome.

Alderman CP, McClure AF, Jersmann HP, Scott SD.

Ann Pharmacother. 1995 Jul-Aug;29(7-8):710-3.

PMID:
8520087
16.
17.

Low-molecular-weight heparin (nadroparin) and very low doses of warfarin in the prevention of upper extremity thrombosis in cancer patients with indwelling long-term central venous catheters: a pilot randomized trial.

Mismetti P, Mille D, Laporte S, Charlet V, Buchmüller-Cordier A, Jacquin JP, Fournel P, Dutrey-Dupagne C, Decousus H; CIP Study Group.

Haematologica. 2003 Jan;88(1):67-73.

18.

Venous thromboembolism and cancer: prevention and therapy.

Lee AY.

Vnitr Lek. 2006 Mar;52 Suppl 1:127-8, 130-1.

PMID:
16637461
19.

Anticoagulants and cancer survival.

Piccioli A, Falanga A, Prandoni P.

Semin Thromb Hemost. 2006 Nov;32(8):810-3. Review.

PMID:
17171594
20.

[Low-molecular-weight heparin for the treatment of acute pulmonary thromboembolism. Comparison with unfractionated intravenous heparin].

Alonso Martínez JL, Abínzano Guillén ML, Solano Remírez M, Alvarez Frías MT, Gutiérrez Dubois J, Munuera García L.

An Med Interna. 2005 Apr;22(4):177-81. Spanish.

PMID:
16004514

Supplemental Content

Support Center